# Controlling the core airway mucin secretion machinery to prevent pathophysiology

> **NIH NIH R01** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2021 · $537,168

## Abstract

Mucus forms an essential barrier that protects the lungs from inhaled particles, pathogens and chemicals.
These toxicants are entrapped in mucus, then swept out of the lungs by ciliary action. Paradoxically however,
mucus dysfunction contributes to the pathobiology of all of the common diseases of the airways, including
asthma, cystic fibrosis and COPD, as well as to interstitial lung diseases. Mucin glycoproteins are the principal
macromolecular component of mucus, responsible for its structure as a semi-solid gel by interacting with
several hundred-fold their mass of water. Mucins are secreted both at a low baseline rate and a high
stimulated rate. A common feature of airway mucus dysfunction is the rapid secretion of hyperproduced
mucins into the airway lumen, forming mucus that is excessively viscoelastic and cannot be cleared by ciliary
action. This impedes airflow and provides a protected environment for microbial growth
While the control of mucin production and hydration have been studied intensively, the mechanism of secretion
is incompletely understood. Exocytosis in all eukaryotes is mediated by the cooperative interactions of a
SNARE complex and an SM scaffolding protein, which are the core exocytic machinery. Our studies show that
for some components of this machinery, different isoforms function in basal versus stimulated mucin secretion.
Our central hypothesis is that two different VAMP proteins define two distinct classes of mucin secretory
granules, associated with distinct secretory function and with distinct trafficking regulatory proteins.
Aim 1. Determine the roles of VAMP3 and VAMP8 in defining two distinct structural and functional classes of
mucin secretory granules.
Aim 2. Determine how mucin granules are assembled, from their exit from the trans-Golgi network, through
homotypic fusion, to form two classes of mature fusion-ready granules.
Aim 3. Determine the physiological and pathophysiological consequences of manipulating the traffic of the two
mucin granule classes.
Completion of these aims will provide fundamental understanding of the mucin secretory mechanism, and will
apply that knowledge to test translational strategies for mitigating mucus dysfunction while preserving its
protective benefits.

## Key facts

- **NIH application ID:** 10133121
- **Project number:** 5R01HL129795-06
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Burton F Dickey
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $537,168
- **Award type:** 5
- **Project period:** 2015-09-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10133121

## Citation

> US National Institutes of Health, RePORTER application 10133121, Controlling the core airway mucin secretion machinery to prevent pathophysiology (5R01HL129795-06). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10133121. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*